Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells

被引：46

作者：

Jia, Bin ^{[1
,2
,3
]}

Choy, Edwin ^{[1
,2
]}

Cote, Gregory ^{[1
,2
]}

Harmon, David ^{[1
,2
]}

Ye, Shunan ^{[1
,2
]}

Kan, Quancheng ^{[3
]}

Mankin, Henry ^{[1
,2
]}

Hornicek, Francis ^{[1
,2
]}

Duan, Zhenfeng ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharmacol, Zhengzhou 450052, Henan, Peoples R China

来源：

CANCER LETTERS | 2014年 / 342卷 / 01期

基金：

美国国家卫生研究院;

关键词：

Kinase; Liposarcoma; CDK11; Tissue microarray; Immunohistochemistry; ADVANCED SOLID TUMORS; SOFT-TISSUE SARCOMA; I CLINICAL-TRIAL; PHASE-I; DEDIFFERENTIATED LIPOSARCOMA; INHIBITOR FLAVOPIRIDOL; C-JUN; OSTEOSARCOMA; EXPRESSION; COMPLEXES;

D O I：

10.1016/j.canlet.2013.08.040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Liposarcoma is the second most common soft tissue sarcoma in adults, but treatment options have been quite limited thus far. In this study, we investigated the functional and therapeutic relevance of cyclin-dependent kinase 11 (CDK11) as a putative target in liposarcoma. CDK11 knockdown by synthetic siRNA or lentiviral shRNA decreased cell proliferation, and induced apoptosis in liposarcoma cells. Moreover, CDK11 knockdown enhances the cytotoxic effect of doxorubicin to inhibit cell growth in liposarcoma cells. These findings suggest that CDK11 is critical for the growth and proliferation of liposarcoma cells. CDK11 may be a promising therapeutic target for the treatment of liposarcoma patients. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：104 / 112

页数：9

共 43 条

[1] Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours [J].

Aleixo, P. B. ;

Hartmann, A. A. ;

Menezes, I. C. ;

Meurer, R. T. ;

Oliveira, A. M. .

JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (12) :1127-1135

[2] Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy [J].

Barretina, Jordi ;

Taylor, Barry S. ;

Banerji, Shantanu ;

Ramos, Alexis H. ;

Lagos-Quintana, Mariana ;

DeCarolis, Penelope L. ;

Shah, Kinjal ;

Socci, Nicholas D. ;

Weir, Barbara A. ;

Ho, Alan ;

Chiang, Derek Y. ;

Reva, Boris ;

Mermel, Craig H. ;

Getz, Gad ;

Antipin, Yevgenyi ;

Beroukhim, Rameen ;

Major, John E. ;

Hatton, Charles ;

Nicoletti, Richard ;

Hanna, Megan ;

Sharpe, Ted ;

Fennell, Tim J. ;

Cibulskis, Kristian ;

Onofrio, Robert C. ;

Saito, Tsuyoshi ;

Shukla, Neerav ;

Lau, Christopher ;

Nelander, Sven ;

Silver, Serena J. ;

Sougnez, Carrie ;

Viale, Agnes ;

Winckler, Wendy ;

Maki, Robert G. ;

Garraway, Levi A. ;

Lash, Alex ;

Greulich, Heidi ;

Root, David E. ;

Sellers, William R. ;

Schwartz, Gary K. ;

Antonescu, Cristina R. ;

Lander, Eric S. ;

Varmus, Harold E. ;

Ladanyi, Marc ;

Sander, Chris ;

Meyerson, Matthew ;

Singer, Samuel .

NATURE GENETICS, 2010, 42 (08) :715-U103

[3] MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes -: A comparative analysis of 559 soft tissue neoplasms with genetic data [J].

Binh, MBN ;

Sastre-Garau, X ;

Guillou, L ;

de Pinieux, G ;

Terrier, P ;

Lagacé, R ;

Aurias, A ;

Hostein, I ;

Coindre, JM .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (10) :1340-1347

[4]

Blachly J.S., 2013, Leukemia and Lymphoma

[5]

Choi H.H., 2012, ONCOGENE

[6] Preclinical study of treatment response in HCT-116 cells and xenografts with 1H-decoupled 31P MRS [J].

Darpolor, Moses M. ;

Kennealey, Peter T. ;

Le, H. Carl ;

Zakian, Kristen L. ;

Ackerstaff, Ellen ;

Rizwan, Asif ;

Chen, Jin-Hong ;

Sambol, Elliot B. ;

Schwartz, Gary K. ;

Singer, Samuel ;

Koutcher, Jason A. .

NMR IN BIOMEDICINE, 2011, 24 (09) :1159-1168

[7] Involvement of c-jun in human liposarcoma growth -: Supporting data from clinical immunohistochemistry and DNAzyme efficacy [J].

Dass, Crispin R. ;

Galloway, Stuart J. ;

Clark, Jonathan C. M. ;

Khachigian, Levon M. ;

Choong, Peter F. M. .

CANCER BIOLOGY & THERAPY, 2008, 7 (08) :1297-1301

[8] Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma [J].

Demicco, Elizabeth G. ;

Torres, Keila E. ;

Ghadimi, Markus P. ;

Colombo, Chiara ;

Bolshakov, Svetlana ;

Hoffman, Aviad ;

Peng, Tingsheng ;

Bovee, Judith V. M. G. ;

Wang, Wei-Lien ;

Lev, Dina ;

Lazar, Alexander J. .

MODERN PATHOLOGY, 2012, 25 (02) :212-221

[9]

Dickson MA, 2013, J CLIN ONCOL, DOI DOI 10.1200/JC0.2012.46.5476

[10] A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol [J].

Dickson, Mark A. ;

Shah, Manish A. ;

Rathkopf, Dana ;

Tse, Archie ;

Carvajal, Richard D. ;

Wu, Nian ;

Lefkowitz, Robert A. ;

Gonen, Mithat ;

Cane, Lauren M. ;

Dials, Heather J. ;

Schwartz, Gary K. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) :1113-1121

← 1 2 3 4 5 →